docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2022-21-1-59-64docru-145Research ArticleГИНЕКОЛОГИЯGYNECOLOGYВзаимодействие вируса Эпштейна — Барр и вируса папилломы человека в канцерогенезе шейки матки. Возможности профилактикиInteraction Between Epstein-Barr Virus and Human Papilloma Virus in Cervical Cancer. Possible Preventionhttps://orcid.org/0000-0002-9106-5277ХлантаД. А.KhlantaD. A.

Хланта Даяна Арсеновна — ординатор, старший лаборант кафедры онкологии и лучевой терапии 

127473, г. Москва, ул. Делегатская, д. 20/1 

20 Delegatskaya St., Bldg. 1, Moscow, 127473

daianakhlanta@gmail.comhttps://orcid.org/0000-0001-8708-2712ГенсГ. П.GuensG. P.

Генс Гелена Петровна — д. м. н., профессор, заведующая кафедрой онкологии и лучевой терапии 

127473, г. Москва, ул. Делегатская, д. 20/1 

20 Delegatskaya St., Bldg. 1, Moscow, 127473

gelena974@gmail.comФГБОУ ВО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Министерства здравоохранения Российской ФедерацииРоссияA.I. Yevdokimov Moscow State University of Medicine and Dentistry (a Federal Government-funded Educational Institution of Higher Education), Russian Federation Ministry of HealthRussian Federation202217022025211ГИНЕКОЛОГИЯ5964Copyright © Хланта Д.А., Генс Г.П., 20252025Хланта Д.А., Генс Г.П.Khlanta D.A., Guens G.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/145Цель обзора

Цель обзора: провести всесторонний анализ потенциальной роли вируса Эпштейна — Барр (ВЭБ) в развитии рака шейки матки.

Основные положения

Основные положения. Вирус папилломы человека (ВПЧ) является основным этиологическим фактором канцерогенеза шейки матки. Однако многие данные, собранные за последние два десятилетия, свидетельствуют о том, что ВЭБ также играет роль в этом процессе; но его вклад в развитие рака шейки матки до сих пор исследован не полностью. В представленном обзоре мы рассмотрим актуальные опубликованные данные о коинфекции ВЭБ и ВПЧ в генезе рака шейки матки, а также потенциальный вклад ВЭБ в прогрессирование гинекологического рака.

Заключение

Заключение. ВЭБ играет важную роль в возникновении и прогрессировании некоторых злокачественных новообразований человека, включая лимфомы (как В-, так и Т-клеточных линий) и карциномы (носоглотки и желудка). Имеющиеся данные свидетельствуют о возможной причинно-следственной связи между ВЭБ и патогенезом рака шейки матки. Часто встречающаяся коинфекция ВЭБ и ВПЧ при раке шейки матки также указывает на потенциальное онкогенное взаимодействие между двумя вирусами. Из этого следует, что необходимы дальнейшие более углубленные исследования для выяснения механизмов синергизма ВЭБ и ВПЧ и его клинического воздействия. С учетом успеха предотвращения рака шейки матки с помощью вакцинации против ВПЧ и предстоящей потенциальной вакцинации против ВЭБ требуется дальнейшее изучение механизма канцерогенеза для улучшения профилактики развития онкологического процесса.

Objective of the Review

Objective of the Review: To comprehensively analyse the potential role of Epstein-Barr virus (EBV) in development of cervical cancer.

Key Points

Key Points. Human papilloma virus (HPV) is a key causative factor of cervical cancer. However, there are a lot of data collected over the last two decades demonstrating that EBV has a role to play in this process; still, its contribution to development of cervical cancer has been studied poorly. This review describes the real-time published data on EBV and HPV co-infection in the genesis of cervical cancer, and the potential role of EBV in gynaecological cancer progression.

Conclusion

Conclusion. EBV has an important role in the genesis and progression of some human malignancies including lymphoid tumours (both В- and Т-cell cancer) and carcinoma (nasopharyngeal and gastric cancer). The available data are indicative of potential cause-effect relations between EBV and cervical cancer pathogenesis. A frequent EBV and HPV co-infection in cervical cancer witnesses possible cancer-causing interaction between the two viruses. Thus, more in-depth studies are needed to find out the mechanisms underlying the EBV and HPV synergism and its clinical effects. Taking into account successful cervical cancer prevention with HPV vaccine and possible future EBV vaccination, the carcinogenesis mechanisms should be studied more thoroughly in order to improve the prevention of oncological diseases.

онкологиявирус Эпштейна — Баррвирус папилломы человекаконинфекциярак шейки маткиoncologyEpstein-Barr virushuman papilloma virusco-infectioncervical cancerReferencesVedham V., Verma M., Mahabir S. Early-life exposures to infectious agents and later cancer development. Cancer Med. 2015; 4(12): 1908–22. DOI: 10.1002/cam4.538Vedham V., Verma M., Mahabir S. Early-life exposures to infectious agents and later cancer development. Cancer Med. 2015; 4(12): 1908–22. DOI: 10.1002/cam4.538Mui U.N., Haley C.T., Tyring S.K. Viral oncology: molecular biology and pathogenesis. J. Clin. Med. 2017; 6(12): 111. DOI: 10.3390/jcm6120111Mui U.N., Haley C.T., Tyring S.K. Viral oncology: molecular biology and pathogenesis. J. Clin. Med. 2017; 6(12): 111. DOI: 10.3390/jcm6120111Weiss R.A. Tumour-inducing viruses. Br. J. Hosp. Med. (Lond.). 2016; 77(10): 565–8. DOI: 10.12968/hmed.2016.77.10.565Weiss R.A. Tumour-inducing viruses. Br. J. Hosp. Med. (Lond.). 2016; 77(10): 565–8. DOI: 10.12968/hmed.2016.77.10.565Esau D. Viral causes of lymphoma: the history of Epstein — Barr virus and human T-lymphotropic virus 1. Virology (Auckl.). 2017; 8: 1178122X17731772. DOI: 10.1177/1178122X17731772Esau D. Viral causes of lymphoma: the history of Epstein — Barr virus and human T-lymphotropic virus 1. Virology (Auckl.). 2017; 8: 1178122X17731772. DOI: 10.1177/1178122X17731772Alipour M. Molecular mechanism of Helicobacter pylori-induced gastric cancer. J. Gastrointest. Cancer. 2021; 52(1): 23–30. DOI: 10.1007/s12029-020-00518-5Alipour M. Molecular mechanism of Helicobacter pylori-induced gastric cancer. J. Gastrointest. Cancer. 2021; 52(1): 23–30. DOI: 10.1007/s12029-020-00518-5de Martel C., Georges D., Bray F. et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health. 2020; 8(2): e180–90. DOI: 10.1016/S2214-109X(19)30488-7de Martel C., Georges D., Bray F. et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health. 2020; 8(2): e180–90. DOI: 10.1016/S2214-109X(19)30488-7Shi Y., Peng S.-L., Yang L.-F. et al. Co-infection of Epstein — Barr virus and human papillomavirus in human tumorigenesis. Chin. J. Cancer. 2016; 35: 16. DOI: 10.1186/s40880-016-0079-1Shi Y., Peng S.-L., Yang L.-F. et al. Co-infection of Epstein — Barr virus and human papillomavirus in human tumorigenesis. Chin. J. Cancer. 2016; 35: 16. DOI: 10.1186/s40880-016-0079-1Cunnea P., Fotopoulou C., Ploski J. et al. Changes in stem cell regulation and epithelial organisation during carcinogenesis and disease progression in gynaecological malignancies. Cancers (Basel.). 2021; 13(13): 3349. DOI: 10.3390/cancers13133349Cunnea P., Fotopoulou C., Ploski J. et al. Changes in stem cell regulation and epithelial organisation during carcinogenesis and disease progression in gynaecological malignancies. Cancers (Basel.). 2021; 13(13): 3349. DOI: 10.3390/cancers13133349Djaoud Z., Guethlein L.A., Horowitz A. et al. Two alternate strategies for innate immunity to Epstein — Barr virus: one using NK cells and the other NK cells and γδ T cells. J. Exp. Med. 2017; 214(6): 1827–41. DOI: 10.1084/jem.20161017Djaoud Z., Guethlein L.A., Horowitz A. et al. Two alternate strategies for innate immunity to Epstein — Barr virus: one using NK cells and the other NK cells and γδ T cells. J. Exp. Med. 2017; 214(6): 1827–41. DOI: 10.1084/jem.20161017Longnecker R.M., Kieff E., Cohen J.I. Epstein — Barr virus. In: Fields B.N., Knipe D.M., Howley P.M., eds. Fields virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013: 1898–959.Longnecker R.M., Kieff E., Cohen J.I. Epstein — Barr virus. In: Fields B.N., Knipe D.M., Howley P.M., eds. Fields virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013: 1898–959.Styczynski J., Tridello G., Gil L. et al. Impact of donor Epstein — Barr virus serostatus on the incidence of graft-versus-host disease in patients with acute leukemia after hematopoietic stem-cell transplantation: a study from the acute leukemia and infectious diseases working parties of the European Society for Blood and Marrow Transplantation. J. Clin. Oncol. 2016; 34(19): 2212–20. DOI: 10.1200/JCO.2015.64.2405Styczynski J., Tridello G., Gil L. et al. Impact of donor Epstein — Barr virus serostatus on the incidence of graft-versus-host disease in patients with acute leukemia after hematopoietic stem-cell transplantation: a study from the acute leukemia and infectious diseases working parties of the European Society for Blood and Marrow Transplantation. J. Clin. Oncol. 2016; 34(19): 2212–20. DOI: 10.1200/JCO.2015.64.2405Chen L., Qiu X., Zhang N. et al. APOBEC-mediated genomic alterations link immunity and viral infection during human papillomavirus-driven cervical carcinogenesis. Biosci. Trends. 2017; 11: 383–8. DOI: 10.5582/bst.2017.01103Chen L., Qiu X., Zhang N. et al. APOBEC-mediated genomic alterations link immunity and viral infection during human papillomavirus-driven cervical carcinogenesis. Biosci. Trends. 2017; 11: 383–8. DOI: 10.5582/bst.2017.01103de Lima M.A.P., Neto P.J.N., Lima L.P.M. et al. Association between Epstein — Barr virus (EBV) and cervical carcinoma: a metaanalysis. Gynecol. Oncol. 2018; 148(2): 317–28. DOI: 10.1016/j.ygyno.2017.10.005de Lima M.A.P., Neto P.J.N., Lima L.P.M. et al. Association between Epstein — Barr virus (EBV) and cervical carcinoma: a metaanalysis. Gynecol. Oncol. 2018; 148(2): 317–28. DOI: 10.1016/j.ygyno.2017.10.005Blanco R., Carrillo-Beltrán D., Osorio J.C. et al. Role of Epstein — Barr virus and human papillomavirus coinfection in cervical cancer: epidemiology, mechanisms and perspectives. pathogens. 2020; 9(9): 685. DOI: 10.3390/pathogens9090685Blanco R., Carrillo-Beltrán D., Osorio J.C. et al. Role of Epstein — Barr virus and human papillomavirus coinfection in cervical cancer: epidemiology, mechanisms and perspectives. pathogens. 2020; 9(9): 685. DOI: 10.3390/pathogens9090685IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr. Eval Carcinog. Risks Hum. 2007; 90: 1–636.IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr. Eval Carcinog. Risks Hum. 2007; 90: 1–636.International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int. J. Cancer. 2007; 120(4): 885–91. DOI: 10.1002/ijc.22357International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int. J. Cancer. 2007; 120(4): 885–91. DOI: 10.1002/ijc.22357Morales-Sánchez A., Fuentes-Pananá E.M. Human viruses and cancer. Viruses. 2014; 6(10): 4047–79. DOI: 10.3390/v6104047Morales-Sánchez A., Fuentes-Pananá E.M. Human viruses and cancer. Viruses. 2014; 6(10): 4047–79. DOI: 10.3390/v6104047Hatta M.N.A., Mohamad Hanif E.A., Chin S.F. et al. Pathogens and carcinogenesis: a review. Biology (Basel). 2021; 10(6): 533. DOI: 10.3390/biology10060533Hatta M.N.A., Mohamad Hanif E.A., Chin S.F. et al. Pathogens and carcinogenesis: a review. Biology (Basel). 2021; 10(6): 533. DOI: 10.3390/biology10060533Suresh A., Suresh P., Biswas R. et al. Prevalence of high-risk HPV and its genotypes-Implications in the choice of prophylactic HPV vaccine. J. Med. Virol. 2021; 93(8): 5188–92. DOI: 10.1002/jmv.27015Suresh A., Suresh P., Biswas R. et al. Prevalence of high-risk HPV and its genotypes-Implications in the choice of prophylactic HPV vaccine. J. Med. Virol. 2021; 93(8): 5188–92. DOI: 10.1002/jmv.27015Okunade K.S. Human papillomavirus and cervical cancer. J. Obstet. Gynaecol. 2020; 40(5): 602–8. DOI: 10.1080/01443615.2019.1634030Okunade K.S. Human papillomavirus and cervical cancer. J. Obstet. Gynaecol. 2020; 40(5): 602–8. DOI: 10.1080/01443615.2019.1634030de Martel C., Plummer M., Vignat J. et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer. 2017; 141(4): 664–70. DOI: 10.1002/ijc.30716de Martel C., Plummer M., Vignat J. et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer. 2017; 141(4): 664–70. DOI: 10.1002/ijc.30716Staats P.N., Davey D.D., Witt B.L. et al. Performance of specific morphologic features in distinguishing low-grade squamous intraepithelial lesions from high-grade squamous intraepithelial lesionsin borderline cases: a College of American Pathologists Cytopathology Committee multiobserver study. J. Am. Soc. Cytopathol. 2021; S2213- 2945(21)00264-7. DOI: 10.1016/j.jasc.2021.11.001Staats P.N., Davey D.D., Witt B.L. et al. Performance of specific morphologic features in distinguishing low-grade squamous intraepithelial lesions from high-grade squamous intraepithelial lesionsin borderline cases: a College of American Pathologists Cytopathology Committee multiobserver study. J. Am. Soc. Cytopathol. 2021; S2213- 2945(21)00264-7. DOI: 10.1016/j.jasc.2021.11.001Näher H., Gissmann L., Freese U.K. et al. Subclinical Epstein — Barr virus infection of both the male and female genital tract — indication for sexual transmission. J. Invest. Dermatol. 1992; 98(5): 791–3. DOI: 10.1111/1523-1747.ep12499958Näher H., Gissmann L., Freese U.K. et al. Subclinical Epstein — Barr virus infection of both the male and female genital tract — indication for sexual transmission. J. Invest. Dermatol. 1992; 98(5): 791–3. DOI: 10.1111/1523-1747.ep12499958Sixbey J.W., Lemon S.M., Pagano J.S. A second site for Epstein — Barr virus shedding: the uterine cervix. Lancet. 1986; 2(8516): 1122–4. DOI: 10.1016/s0140-6736(86)90531-3Sixbey J.W., Lemon S.M., Pagano J.S. A second site for Epstein — Barr virus shedding: the uterine cervix. Lancet. 1986; 2(8516): 1122–4. DOI: 10.1016/s0140-6736(86)90531-3Guidry J.T., Scott R.S. The interaction between human papillomavirus and other viruses. Virus Res. 2017; 231: 139–47. DOI: 10.1016/j.virusres.2016.11.002Guidry J.T., Scott R.S. The interaction between human papillomavirus and other viruses. Virus Res. 2017; 231: 139–47. DOI: 10.1016/j.virusres.2016.11.002Yefenof E. Epstein Barr virus (EBV) and complement (C3) interactions with human lymphoid cells. Haematol. Blood Transfus. 1979; 23: 237–8. DOI: 10.1007/978-3-642-67057-2-30Yefenof E. Epstein Barr virus (EBV) and complement (C3) interactions with human lymphoid cells. Haematol. Blood Transfus. 1979; 23: 237–8. DOI: 10.1007/978-3-642-67057-2-30Justiz Vaillant A.A., Vashisht R., Zito P.M. Immediate hypersensitivity reactions. In: StatPearls. Treasure Island (FL): StatPearls Publishing; November 15, 2021.Justiz Vaillant A.A., Vashisht R., Zito P.M. Immediate hypersensitivity reactions. In: StatPearls. Treasure Island (FL): StatPearls Publishing; November 15, 2021.Castro D., Vera J.D., Soto-Becerra P. et al. Epstein — Barr virus and its prognostic value in a cohort of Peruvian women with cervical cancer. medRxiv. 2020.08.04.20167841. DOI: 10.1101/2020.08.04.20167841Castro D., Vera J.D., Soto-Becerra P. et al. Epstein — Barr virus and its prognostic value in a cohort of Peruvian women with cervical cancer. medRxiv. 2020.08.04.20167841. DOI: 10.1101/2020.08.04.20167841Feng M., Duan R., Gao Y. et al. Role of Epstein — Barr virus and human papillomavirus coinfection in cervical intraepithelial neoplasia in Chinese women living with HIV. Front. Cell Infect. Microbiol. 2021; 11: 703259. DOI: 10.3389/fcimb.2021.703259Feng M., Duan R., Gao Y. et al. Role of Epstein — Barr virus and human papillomavirus coinfection in cervical intraepithelial neoplasia in Chinese women living with HIV. Front. Cell Infect. Microbiol. 2021; 11: 703259. DOI: 10.3389/fcimb.2021.703259Klymenko T., Gu Q., Herbert I. et al. RNA-Seq analysis of differentiated keratinocytes reveals a massive response to late events during human papillomavirus 16 infection, including loss of epithelial barrier function. J. Virol. 2017; 91(24): e01001–17. DOI: 10.1128/JVI.01001-17Klymenko T., Gu Q., Herbert I. et al. RNA-Seq analysis of differentiated keratinocytes reveals a massive response to late events during human papillomavirus 16 infection, including loss of epithelial barrier function. J. Virol. 2017; 91(24): e01001–17. DOI: 10.1128/JVI.01001-17Wang L.W., Jiang S., Gewurz B.E. Epstein — Barr virus LMP1-mediated oncogenicity. J. Virol. 2017; 91(21): e01718–16. DOI: 10.1128/JVI.01718-16Wang L.W., Jiang S., Gewurz B.E. Epstein — Barr virus LMP1-mediated oncogenicity. J. Virol. 2017; 91(21): e01718–16. DOI: 10.1128/JVI.01718-16Aromseree S., Middeldorp J.M., Pientong C. et al. High levels of EBVencoded RNA 1 (EBER1) trigger interferon and inflammation-related genes in keratinocytes expressing HPV16 E6/E7. PLoS One. 2017; 12(1): e0169290. DOI: 10.1371/journal.pone.0169290Aromseree S., Middeldorp J.M., Pientong C. et al. High levels of EBVencoded RNA 1 (EBER1) trigger interferon and inflammation-related genes in keratinocytes expressing HPV16 E6/E7. PLoS One. 2017; 12(1): e0169290. DOI: 10.1371/journal.pone.0169290Lan T., Chen L., Wei X. Inflammatory cytokines in cancer: comprehensive understanding and clinical progress in gene therapy. Cells. 2021; 10(1): 100. DOI: 10.3390/cells10010100Lan T., Chen L., Wei X. Inflammatory cytokines in cancer: comprehensive understanding and clinical progress in gene therapy. Cells. 2021; 10(1): 100. DOI: 10.3390/cells10010100Fishbein A., Hammock B.D., Serhan C.N. et al. Carcinogenesis: failure of resolution of inflammation? Pharmacol. Ther. 2021; 218: 107670. DOI: 10.1016/j.pharmthera.2020.107670Fishbein A., Hammock B.D., Serhan C.N. et al. Carcinogenesis: failure of resolution of inflammation? Pharmacol. Ther. 2021; 218: 107670. DOI: 10.1016/j.pharmthera.2020.107670Cyprian F.S., Al-Farsi H.F., Vranic S. et al. Epstein — Barr virus and human papillomaviruses interactions and their roles in the initiation of epithelial-mesenchymal transition and cancer progression. Front. Oncol. 2018; 8: 111. DOI: 10.3389/fonc.2018.00111Cyprian F.S., Al-Farsi H.F., Vranic S. et al. Epstein — Barr virus and human papillomaviruses interactions and their roles in the initiation of epithelial-mesenchymal transition and cancer progression. Front. Oncol. 2018; 8: 111. DOI: 10.3389/fonc.2018.00111Elgui de Oliveira D., Müller-Coan B.G., Pagano J.S. Viral carcinogenesis beyond malignant transformation: EBV in the progression of human cancers. Trends Microbiol. 2016; 24(8): 649–64. DOI: 10.1016/j.tim.2016.03.008Elgui de Oliveira D., Müller-Coan B.G., Pagano J.S. Viral carcinogenesis beyond malignant transformation: EBV in the progression of human cancers. Trends Microbiol. 2016; 24(8): 649–64. DOI: 10.1016/j.tim.2016.03.008Chen X., Bode A.M., Dong Z. et al. The epithelial-mesenchymal transition (EMT) is regulated by oncoviruses in cancer. FASEB J. 2016; 30(9): 3001–10. DOI: 10.1096/fj.201600388RChen X., Bode A.M., Dong Z. et al. The epithelial-mesenchymal transition (EMT) is regulated by oncoviruses in cancer. FASEB J. 2016; 30(9): 3001–10. DOI: 10.1096/fj.201600388RFontham E.T.H., Wolf A.M.D., Church T.R. et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J. Clin. 2020; 70(5): 321–46. DOI: 10.3322/caac.21628Fontham E.T.H., Wolf A.M.D., Church T.R. et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J. Clin. 2020; 70(5): 321–46. DOI: 10.3322/caac.21628Committee Opinion No. 704: human papillomavirus vaccination. Obstet. Gynecol. 2017; 129(6): 1. DOI: 10.1097/AOG.0000000000002052Committee Opinion No. 704: human papillomavirus vaccination. Obstet. Gynecol. 2017; 129(6): 1. DOI: 10.1097/AOG.0000000000002052Rosalik K., Tarney C., Han J. Human papilloma virus vaccination. Viruses. 2021; 13(6): 1091. DOI: 10.3390/v13061091Rosalik K., Tarney C., Han J. Human papilloma virus vaccination. Viruses. 2021; 13(6): 1091. DOI: 10.3390/v13061091Филиппов О.В., Большакова Л.Н., Елагина Т.Н. и др. Региональный календарь профилактических прививок в Москве: история, развитие, перспективы. Эпидемиология и вакцинопрофилактика. 2020; 19(4): 63–75. DOI: 10.31631/2073-3046-2020-19-4-63-75Filippov O.V., Bolshakova L.N., Elagina T.N. et al. Regional schedule of vaccination in Moscow: history, development, prospects. Epidemiology and Vaccinal Prevention. 2020; 19(4): 63–75. (in Russian. DOI: 10.31631/2073-3046-2020-19-4-63-75Dilley S., Miller K.M., Huh W.K. Human papillomavirus vaccination: ongoing challenges and future directions. Gynecol. Oncol. 2020; 156(2): 498–502. DOI: 10.1016/j.ygyno.2019.10.018Dilley S., Miller K.M., Huh W.K. Human papillomavirus vaccination: ongoing challenges and future directions. Gynecol. Oncol. 2020; 156(2): 498–502. DOI: 10.1016/j.ygyno.2019.10.018Safaeian M., Sampson J.N., Pan Y. et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: the CVT trial. J. Natl. Cancer Inst. 2018; 110(2): 205–12. DOI: 10.1093/jnci/djx158Safaeian M., Sampson J.N., Pan Y. et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: the CVT trial. J. Natl. Cancer Inst. 2018; 110(2): 205–12. DOI: 10.1093/jnci/djx158Kjaer S.K., Nygård M., Dillner J. et al. A 12-year follow-up on the longterm effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries. Clin. Infect. Dis. 2017; 66(3): 339–45. DOI: 10.1093/cid/cix797Kjaer S.K., Nygård M., Dillner J. et al. A 12-year follow-up on the longterm effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries. Clin. Infect. Dis. 2017; 66(3): 339–45. DOI: 10.1093/cid/cix797Arbyn M., Xu L., Simoens C. et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst. Rev. 2018; 5(5): CD009069. DOI: 10.1002/14651858.CD009069.pub3Arbyn M., Xu L., Simoens C. et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst. Rev. 2018; 5(5): CD009069. DOI: 10.1002/14651858.CD009069.pub3Palmer T., Wallace L., Pollock K.G. et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12–13 in Scotland: retrospective population study. BMJ. 2019; 365: l1161. DOI: 10.1136/bmj.l1161Palmer T., Wallace L., Pollock K.G. et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12–13 in Scotland: retrospective population study. BMJ. 2019; 365: l1161. DOI: 10.1136/bmj.l1161Dunmire S.K., Verghese P.S., Balfour H.H. Jr. Primary Epstein — Barr virus infection. J. Clin. Virol. 2018; 102: 84–92. DOI: 10.1016/j.jcv.2018.03.001Dunmire S.K., Verghese P.S., Balfour H.H. Jr. Primary Epstein — Barr virus infection. J. Clin. Virol. 2018; 102: 84–92. DOI: 10.1016/j.jcv.2018.03.001Rajcani J., Banati F., Szenthe K. et al. The potential of currently unavailable herpes virus vaccines. Expert Rev. Vaccines. 2018; 17: 239– 48. DOI: 10.1080/14760584.2018.1425620Rajcani J., Banati F., Szenthe K. et al. The potential of currently unavailable herpes virus vaccines. Expert Rev. Vaccines. 2018; 17: 239– 48. DOI: 10.1080/14760584.2018.1425620Shannon-Lowe C., Rickinson A. The global landscape of EBV-associated tumors. Front. Oncol. 2019; 9: 713. DOI: 10.3389/fonc.2019.00713Shannon-Lowe C., Rickinson A. The global landscape of EBV-associated tumors. Front. Oncol. 2019; 9: 713. DOI: 10.3389/fonc.2019.00713Rühl J., Leung C.S., Münz C. Vaccination against the Epstein — Barr virus. Cell Mol. Life Sci. 2020; 77(21): 4315–24. DOI: 10.1007/s00018-020-03538-3Rühl J., Leung C.S., Münz C. Vaccination against the Epstein — Barr virus. Cell Mol. Life Sci. 2020; 77(21): 4315–24. DOI: 10.1007/s00018-020-03538-3

The authors declare that there are no conflicts of interest present.